


Renalyx launches world's first indigenous AI based smart hemodialysis machine

11 June 2025 | News

To invest Rs 800 crore in the next four years to build a robust manufacturing capacity



Bengaluru-based Renalyx Health Systems has launched RENALYX – RxT 21, world's first fully indigenous, artificial intelligence (AI) and cloud-enabled smart hemodialysis machine with real-time remote monitoring and clinical connectivity facility.

Price starting at Rs 6.7 lakh - significantly lower than the imported machines - RENALYX – RxT 21 will make dialysis affordable and accessible to a larger population and bridge the demand-supply gap in the renal care across semi-urban and rural regions.

Completely designed and manufactured in India, RENALYX – RxT 21 leverages latest technologies including cloud-based telenephrology platforms to offer safety and quality care to kidney patients, end-stage renal disease (ESRD) patients especially those with cardiovascular, pulmonary and acute kidney injury-related issues.

RENALYX – RxT 21 makes Renalyx the sixth company globally and first in India to produce an advanced dialysis machine with EU CE certification.

Renalyx has plans to invest Rs 800 crore in the next four years to build the manufacturing capacity of 5,000 machines by FY25-26 and will develop additional capacity of 1500 machines by FY27-28. The company also have plans to manufacture consumables indigenously. The company has manufacturing facilities at Bengaluru and Mysuru in Karnataka and at Mumbai in Maharashtra to support its scale-up plans and meet the growing demand.

The company plans to raise funds through the sale of equity, backed by strong interest from prominent Indian and international investors. In addition, it will raise debt, and the promoters will also invest capital. Renalyx also has plans to go public within the next three years.

With initial deployments of the machine planned in Maharashtra and Karnataka, Renalyx will go for rapid pan-India distribution of RENALYX – RxT 21 with its partners as well as exports to other countries. The company has successfully penetrated international markets, securing orders from South Africa, the USA, and Europe.

The Indian CDSCO approval of the machine is in its final stages and is expected by July 2025, while the US FDA approval process is underway and anticipated by March 2026.

Renalyx plans to install RxT 21 at primary health centres (PHC), community health centres (CHC), private dialysis centres and hospitals to make renal care available to a large number of people.

The company, in collaboration with its partner, will set up franchise centres across India and in international markets.

In addition, Renalyx has awarded manufacturing license to Bharat Electronics Ltd. (BEL) to produce 6,000 RENALYX – RxT 17 in the next three years. RENALYX – RxT 17 is a previously launched dialysis machine by Renalyx which comes with standard features and facilities.